A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Active:	Yes
Cancer Type:	Bladder Cancer Breast Cancer Colon/Rectal Cancer Head and Neck Cancer Kidney Cancer Lung Cancer Ovarian Cancer Unknown Primary	NCT ID:	NCT06120075
Trial Phases:	Phase I	Protocol IDs:	ARC-27 (primary) NCI-2024-03901
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Arcus Biosciences, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT06120075

Summary

The primary purpose of this study is to assess the safety and tolerability of AB801 in
participants with advanced malignancies, and to determine a recommended AB801 dose for
expansion.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.